HSBC Holdings plc vs uniQure N.V. Ordinary Shares — how do they compare? HSBC Holdings plc trades at $95.11 (market cap $322.45B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: HSBC Holdings plc is far larger — about 222.4× uniQure N.V. Ordinary Shares's market cap, and HSBC Holdings plc pays a 3.99% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HSBC | QURE | |
|---|---|---|
Market Cap | $322.45B | $1.45B |
Volume | 2,058,215 | 3,323,243 |
Sector | Financials | Health |
52-Week High | $107.86 | $70.59 |
52-Week Low | $65.67 | $9.03 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $707.46M |
Dividend Yield | 3.99% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with a bearish technical signal from moving averages and ADX. The stock shows solid fundamentals with a P/E of 13.55, net income margin of 34.54%, and recent earnings beats in Q4 2025 and Q2 2026. Recent news highlights strategic expansions in TMT banking and India equity broking, alongside a planned CFO transition in 2027.
The outlook is mixed: valuation appears reasonable and profitability is strong, but technical indicators signal caution and analyst consensus leans Hold. Key risks include execution of growth initiatives and macroeconomic pressures. The stock offers income with a $0.50 dividend, but investors should weigh near-term technical weakness against long-term fundamental strength.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →